Meeting
2024 ASCO Breakthrough
A potent and selective pan-RAS inhibitor, ADT-1004, targeting complex KRAS mutations for pancreatic cancer.
Authors
Gary Piazza
Auburn University, Auburn, AL
Gary Piazza , Reddy DS Bandi , Jeremy B Foote , Adam B Keeton , Tyler Ernest Mattox , Xi Chen , Yulia Maxuitenko , Upender Manne , Michael R Boyd , Donald J Buchsbaum , Bassel F. El-Rayes
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A
Track
Gastrointestinal Cancer,Central Nervous System Tumors,Developmental Therapeutics,Genitourinary Cancer,Quality of Care,Healthcare Equity and Access to Care,Population Health,Viral-Mediated Malignancies
Sub Track
Targeted Therapies
Citation
J Clin Oncol 42, 2024 (suppl 23; abstr 90)
DOI
10.1200/JCO.2024.42.23_suppl.90
Abstract #
90
Poster Bd #
G2
Abstract Disclosures
Similar Posters
Poster
2018 Gastrointestinal Cancers Symposium
Comprehensive genomic profiling (CGP) in KRAS wild-type (WT) pancreatic ductal adenocarcinoma (PDAC).
First Author: Ben George
Poster
2024 ASCO Annual Meeting
KRAS mutations allelic frequency dynamics using plasma extracellular vesicles: Association with survival outcomes in localized pancreatic adenocarcinoma.
First Author: Asmita Chopra
Poster
2024 ASCO Annual Meeting
AMPLIFY-7P, a first-in-human safety and efficacy trial of adjuvant mKRAS-specific lymph node targeted amphiphile ELI-002 7P vaccine in patients with minimal residual disease–positive pancreatic and colorectal cancer.
First Author: Craig E. Devoe
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Clinical impact of KRAS mutations in metastatic pancreatic ductal adenocarcinoma (PDAC).
First Author: Carter Norton